Marco Meglio

The primary pharmaceutical options suggested by national guidelines were considered effective by only 13.8% and 14.9% of the patients with persistent idiopathic facial pain.

Treatment of ALS with tofersen resulted in differences in total cerebrospinal fluid SOD1 protein and neurofilament light chain, both markets of target engagement and neuronal degeneration.

An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.

Roderick Spears, MD, FAHS, FAAN, professor of neurology, University of Pennsylvania, discussed the need to raise awareness of migraine and how the community can build upon the progress made.

The treatment effect observed from nabiximols (Sativex; GW Pharmaceuticals) was significant at all 1-week time points over the course of the 12-week study.

Data from the EXPAND trial show that after 12 months of treatment, changes on retinal nerve fiber layer thickness favored those on siponimod rather than the placebo group.

In data presented at ECTRIMS 2021, from years 1-5, the proportions of patients with relapsing multiple sclerosis achieving NEDA-3 status ranged from 63%to 75%.

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital of Chicago provided knowledge on the how and why diets are constructed for patients with epilepsy.

In the cohort of 14 patients with preoperative impulsive and compulsive behavior burden, 6 patients demonstrated clinically relevant improvement on QUIP-RS, while 1 worsened and 7 remained stable.

Investigators observed a significant difference in the hazard ratio change on NPI apathy score within the first 100 days, suggesting an early treatment effect.

The pivotal phase 3 GRADUATE 1 and 2 trials will evaluate the effect of gantenerumab on amyloid load and downstream biomarkers of disease progression in patients with early Alzheimer disease.

Gennero Pagano, MD, MSc, PhD, expert medical director, Roche, provided thoughts on the investigational agent prasinezumab, overall Parkinson drug development, and MDS Virtual Congress.

Some of the most frequently reported trial criteria were the exclusion of participants with non-AD neurological disease, psychiatric illness, cardiovascular and cerebrovascular disease, obligated caregiver attendance, and cognitive impairment.

Patients who were dementia-free with the lowest PF had smaller volumes of total brain, gray matter, and white matter, and had greater white matter hyperintensities.

Patients treated in the 10- and 20-mg once daily groups showed statistically significant improvements in UPDRS parts II, III, IV, and in total MDS-UPDRS scores compared with baseline.

Evanthia Bernitsas, MD, neurologist, Wayne State University, discussed a recently conducted analysis, which confirmed inebilizumab’s ability to treat African Americans with NMOSD.

None of the associations between blood pressure and outcomes were modified by successful reperfusion at the end of the endovascular treatment procedure.

Most attacks occurred within the first year of inebilizumab treatment, and nearly all participants were attack free in subsequent years following treatment initiation.

The expert medical director at Roche provided context on recently published data, which showed prasinezumab’s positive impact in delaying motor progression in patients with Parkinson disease.

In the largest prospective study evaluating the Penumbra system, 87.4% of patients achieved postprocedure modified Thrombolysis in Cerebral Infarction scores between 2b to 3.

Investigators observed a high prevalence of cerebral microbleeds, cortical superficial siderosis, and history of intracerebral hemorrhage, all well-established surrogate markers of cerebral amyloid angiopathy severity.

During the double-blind treatment phase, rates of hypertension AEs were low for the placebo and erenumab 70- and 140-mg treatment groups, as well as during open-label erenumab treatment.

Differences in response to treatment with levetiracetam (Keppra; UCB Pharma) among individuals with and without epileptiform activity who have Alzheimer disease warrant future investigations of other antiseizure medications in this population, according to study authors.

In preclinical mouse models lacking both dystrophin and utrophin, treatment with an agent using the company's PN chemistry resulted in 100% survival at 40 weeks, setting up the therapy for this phase 1b2/a trial.

After 10-12 months of treatment, 51.2% of patients responded with a clinically meaningful reduction in drop seizures, while 25.3% of patients demonstrated a profound reduction.

Neurology News Network for the week of October 2, 2021. [WATCH TIME: 4 minutes]

David R. Lynch, MD, PhD, professor of neurology, University of Pennsylvania Perelman School of Medicine, discussed why omaveloxolone’s recent success speaks to the progress made within the FA treatment space.

Children and adults with migraine displayed significantly less REM sleep as a percentage of total sleep time than healthy individuals.

Even after excluding those who received ALS diagnosis in the 5 years prior, higher HDL and APOA1 levels were associated with a lower risk of ALS.

The multinational study uses change from baseline to week 12 in total Unified Parkinson’s Disease Rating Scale score, defined as sum of parts II and III scores, as the primary end point.